



***HPTN 035***

***Product Use Management***



Kailazarid Gomez

# Objectives

**1. To discuss protocol specifications for discontinuation of product use and resumption of product use following discontinuation**

**2. To discuss ongoing study participation in relation to discontinuation and resumption of product use**

# Product Discontinuation

- Participants must be discontinued from product use by the study site Investigator or designee in the event of:
  - Pregnancy
  - AE that meets criteria for expedited reporting to DAIDS that is judged probably or definitely related to product use.

# Summary Chart for Expedited AE Reporting to DAIDS

	Standard Level	Intensive Level	Targeted Level
<b>Deaths</b>	All Events	All Events	All Events
<b>Congenital anomalies, birth defects, fetal losses</b>	All Events	All Events	All Events
<b>Disabilities/Incapacities</b>	All Events	All Events	All Events
<b>Hospitalization<sup>1</sup></b>	All Suspected Adverse Drug Reactions	All Suspected Adverse Drug Reactions	Unexpected Suspected Adverse Drug Reactions
<b>Other events</b>	All Grade 4 Suspected Adverse Drug Reactions	All Grades 3 and 4 Suspected Adverse Drug Reactions	Unexpected Life-Threatening Clinical Suspected Adverse Drug Reactions

# Product Discontinuation

- Investigators/designees also may discontinue product use, pending consultation with the PSRT, in the event of:
  - AE that meets criteria for expedited reporting that is judged possibly related to product use
  - Pelvic exam finding involving deep epithelial disruption that does not resolve over the course of an additional month of product use
  - Non-compliance with study procedures
  - Other undue risk to participant safety

# Product Discontinuation

- Participants at sites performing Pap smears will be discontinued from product use in the event of:
  - High-grade squamous intraepithelial lesion or more severe abnormality
- If local standard of care requires clinical colposcopy and biopsy to assess lower grade abnormalities, product use will be discontinued for one week before and two weeks after the procedure. If further intervention is needed, discontinuation will be extended until after treatment and resolution of the abnormality.

# Product Discontinuation

- Participants who become HIV-positive will be offered the option to continue product use unless continued use is not permitted by site regulatory authorities or IRBs/ECs.
- At sites where continued product use is not permitted, product use will be discontinued after HIV infection is confirmed.

# Participant Follow-up During Product Discontinuation

- Participants who discontinue product use are not routinely withdrawn from the study.
- Every effort will be made to complete all protocol-specified follow-up visits and procedures with these participants.
- Participants who become pregnant will be maintained in follow-up through their originally scheduled study exit date or until their pregnancy outcome is ascertained, whichever is longer.

# Resumption of Product Use

- Participants who become pregnant may resume product use 42 days after giving birth or other termination of the pregnancy.
- Participants with abnormal Pap smear results requiring product discontinuation may resume product use after treatment (if required) and resolution of the abnormality.

# April 2005

Sunday	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
					1 Pregnancy Outcome	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30

# May 2005

Sunday	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
1	2	3	4	5	6	7
8	9	10	11	12	13	14 Participant could resume product use (42 days <b>After</b> Pregnancy outcome)
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31				



# Resumption of Product Use

- With approval from the PSRT, participants who discontinue product use due to a probably or definitely related AE that meets criteria for expedited reporting to DAIDS may resume product use after the AE resolves (returns to baseline) or stabilizes at a non-reportable severity grade.

# Conclusion

- Product use management (discontinuation and resumption) is based on participant safety considerations.
- Investigators are responsible for following protocol specifications and for consulting the PSRT as needed.
- Regardless of product management decisions, participants are maintained in follow-up per their original monthly follow-up visit schedule.

# Thank You!

## Questions?

